Differences in patient reported psoriasis symptom severity between patients rated as ‘clear’ versus ‘almost clear’ based on Physician Global Assessment - 09/05/15
Steven Feldman, Wake Forest University School of Medicine, Winston-Salem, NC, United States; Donald Bushnell, Health Research Associates, Mountlake Terrace, WA, United States; Hema Viswanathan, Amgen Inc, Thousand Oaks, CA, United States; Mona Martin, Health Research Associates, Mountlake Terrace, WA, United States; Sally Wade, Wade Outcomes Research and Consulting, Salt Lake City, UT, United States; Michael Scanlon, Health Research Associates, Mountlake Terrace, WA, United States; Wenjing Yang, Amgen Inc, Thousand Oaks, CA, United States; Lionel Pinto, Amgen Inc, Thousand Oaks, CA, United States; Leon Kircik, Icahn School of Medicine, Mount Sinai, Louisville, KY, United States; Paul Klekotka, Amgen Inc, Thousand Oaks, CA, United States
Il testo completo di questo articolo è disponibile in PDF.| Study funded by Amgen Inc. |
Vol 72 - N° 5S1
P. AB230 - maggio 2015 Ritorno al numero
Articolo precedente
- Development of severe psoriasis scalp with alopecia during treatment of Crohn’s disease with infliximab: A paradoxical side effect
- Disconnect between radiographic progression and skin or arthritic outcomes in psoriatic arthritis patients treated with adalimumab
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?